medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2022, Number 2

<< Back Next >>

Rev ADM 2022; 79 (2)

Solid ameloblastoma: review of the literature and case report.

Carrasco RCA, Vinitzky BI, Miranda QTK, Fernández MEE, Aldape BBC

Language: Spanish
References: 23
Page: 103-108
PDF size: 336.14 Kb.


ABSTRACT

Ameloblastoma is a benign odontogenic tumor that can originate from the odontogenic epithelium, the enamel organ, remnants of the dental lamina of the epithelium of odontogenic cysts, or from the basal cells of the epithelium of the oral mucosa. It has slow intraosseous growth, has the capacity to be locally invasive, perforating or expanding the bone cortices with a high incidence of local recurrence if it is not treated properly. 87% of the reported cases have been located in the posterior region of the mandible (body, angle and ascending ramus). It has a predilection for the male sex (53.2%) over the female gender (46.7%), it can occur at any age, however, the highest incidence is between 20 and 50 years. The treatment of choice is surgical. The case of a 58-year-old male patient is presented with a diagnosis of follicular solid ameloblastoma that covers the posterior part of the body and the ascending branch treated in a radical way, performing hemimandibulectomy.


REFERENCES

  1. Laxmidevi BL, Kokila G, Mahadesh J. Ameloblastoma-adding perspectives. Journal of Dental Sciences and Research. 2010; 1 (2): 11-22.

  2. Wright JM, Vered M. Update from the 4th edition of the World Health Organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors. Head Neck Pathol. 2017; 11 (1): 68-77.

  3. Cueva Y, Calderón V, Trevejo-Bocanegra AP. El uso del contraste para el diagnóstico de ameloblastoma: a propósito de un caso. Revista Estomatológica Herediana. 2017; 27 (1): 44-50.

  4. Heikinheimo K, Kurppa KJ, Elenius K. Novel targets for the treatment of ameloblastoma. J Dent Res. 2015; 94 (2): 237-240.

  5. Hendra FN, Van Cann EM, Helder MN, Ruslin M, de Visscher JG, Forouzanfar T et al. Global incidence and profile of ameloblastoma: a systematic review and meta-analysis. Oral Dis. 2020; 26 (1): 12-21. doi: 10.1111/odi.13031.

  6. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol. 2007; 30 (6): 645-648.

  7. Yang R, Liu Z, Peng C, Cao W, Ji T. Maxillary ameloblastoma: factors associated with risk of recurrence. Head Neck. 2017; 39 (5): 996-1000.

  8. Bilodeau EA, Seethala RR. Update on Odontogenic tumors: proceedings of the North American head and neck pathology society. Head Neck Pathol. 2019; 13 (3): 457-465.

  9. Bianchi B, Ferri A, Ferrari S, Leporati M, Copelli C, Ferri T et al. Mandibular resection and reconstruction in the management of extensive ameloblastoma. Oral Maxillofac Surg. 2013; 71 (3): 528-537.

  10. Ruquaya M, Singh VP. Ameloblastoma - a locally destructive and invasive tumour-review of literature. Int J Otolaryngol Head Neck Surg. 2014; 3: 216-222.

  11. Harnsberger R. Ameloblastoma. En: Diagnostic imaging head and neck. Utah: Amirsys. 2004, 10-13.

  12. Chauhan DS, Guruprasad Y. Plexiform ameloblastoma of the mandible. J Clin Imaging Sci. 2011; 1 (4): 61.

  13. Hertog D, Van der Waal I. Ameloblastoma of the jaws: a critical reappraisal based on a 40-years single institution experience. Oral Oncol. 2010; 46 (1): 61-64.

  14. Chaine A, Pitak-Arnnop P, Dhanuthai K, Ruhin-Poncet B, Bertrand JC, Bertolus C. A treatment algorithm for managing giant mandibular ameloblastoma: 5-year experiences in a Paris university hospital. Eur J Surg Oncol. 2009; 35 (9): 999-1005.

  15. Hammarfjord O, Roslund J, Abrahamsson P, Nilsson P, Thor A, Magnusson M et al. Surgical treatment of recurring ameloblastoma, are there options? Br J Oral Maxillofac Surg. 2013; 51 (8): 762-766.

  16. Camargo P, Olaya GE, Torres ME. Teorías del crecimiento craneofacial: una revisión de literatura. Ustasalud. 2017; 16: 78-88.

  17. Kurppa KJ, Catón J, Morgan PR, Ristimaki A, Ruhin B, Kellokoski J et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014; 232 (5): 492-498.

  18. Mishra P, Panda A, Bandyopadhyay A, Kumar H, Mohiddin G. Sonic hedgehog signalling pathway and ameloblastoma – a review. J Clin Diagn Res. 2015; 9 (11): ZE10-ZE13.

  19. Vidal GM, Anguiano JLC, Galindo PM. Tratamiento de ameloblastoma convencional: hemimandibulectomía, y reconstrucción con placa 2.4 bloqueada con aditamento condilar Synthes. Reporte de un caso. Revista ADM. 2015; 72 (3): 153-159.

  20. Martínez-Martínez M, Mosqueda-Taylor A, Carlos-Bregni R, Pires FR, Delgado-Azañero W, Neves-Silva R et al. Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas. Med Oral Patol Oral Cir Bucal. 2017; 22 (3): e324-e332.

  21. Lei Y, Jaradat JM, Owosho A, Adebiyi KE, Lybrand KS, Neville BW et al. Evaluation of SOX2 as a potential marker for ameloblastic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117 (5): 608-616.e1. doi: 10.1016/j.oooo.2014.01.017.

  22. Kalaskar R, Unawane AS, Kalaskar AR, Pandilwar P. Conservative management of unicystic ameloblastoma in a young child: report of two cases. Contemp Clin Dent. 2011; 2 (4): 359-363.

  23. Brown NA, Betz BL. Ameloblastoma: a review of recent molecular pathogenetic discoveries. Biomark Cancer. 2015; 7 (Suppl 2): 19-24.




2020     |     www.medigraphic.com